GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Notes Receivable

Halberd (Halberd) Notes Receivable : $0.00 Mil (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Notes Receivable?

Halberd's Notes Receivable for the quarter that ended in Jul. 2023 was $0.00 Mil.

Halberd Notes Receivable Historical Data

The historical data trend for Halberd's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Notes Receivable Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Notes Receivable
- - -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Notes Receivable - - -

Halberd Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Halberd Notes Receivable Related Terms

Thank you for viewing the detailed overview of Halberd's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Notes Receivable
Comparable Companies
TSSI SWMM SFHI VSR ETOLF ESOA ENG LYOPF BBHDF RCMT LMB CUUHF GV IBIBF LAYN EMFGF LOUIF ORN WLDN GLDD
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Website
https://www.halberdcorporation.com
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236